Bernard Chevalier

A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial

Patrick W. Serruys, Bernard Chevalier, Dariusz Dudek et al. · The Lancet · 2014 · 556 citations · Full text

Percutaneous Coronary Intervention, Absorb Ii, Endovascular Technique +11

Transfemoral Aortic Valve Implantation

Kentaro Hayashida, Thierry Lefèvre, Bernard Chevalier et al. · JACC: Cardiovascular Interventions · 2011 · 548 citations

Vascular Surgery, Valve Disease, Surgery +3

Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial

Patrick W. Serruys, Bernard Chevalier, Yohei Sotomi et al. · The Lancet · 2016 · 534 citations · Full text

Percutaneous Coronary Intervention, Absorb Ii, Everolimus-eluting Metallic Stent +10

Evaluation of the Second Generation of a Bioresorbable Everolimus-Eluting Vascular Scaffold for the Treatment of De Novo Coronary Artery Stenosis

Patrick W. Serruys, Yoshinobu Onuma, Dariusz Dudek et al. · Journal of the American College of Cardiology · 2011 · 525 citations

Tissue Engineering, Percutaneous Coronary Intervention, Engineering +11

Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk

Marco Valgimigli, Enrico Frigoli, Dik Heg et al. · New England Journal of Medicine · 2021 · 507 citations · Full text